Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Mantra on Hypertensive Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03555344
Recruitment Status : Completed
First Posted : June 13, 2018
Last Update Posted : July 17, 2018
Sponsor:
Collaborators:
Warwick Research Services
Swamigal Trust for Vedic Science, India
Information provided by (Responsible Party):
NMP Medical Research Institute

Brief Summary:
Mantras are specialized energized sound or words, which are defined most important sound therapy in Vedic healing. Present study was undertaken to evaluate the immediate effect of specialized Mantra chant on cardiovascular parameters in high blood pressure patients.

Condition or disease Intervention/treatment Phase
High Blood Pressure Other: Mantra Chikitsa Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Immediate Effect of Mantra Chikitsa on Cardiovascular Parameters in Hypertensive Patients
Actual Study Start Date : October 28, 2017
Actual Primary Completion Date : May 15, 2018
Actual Study Completion Date : May 30, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Mantra Chikitsa
Mantra chanting for 15 mins
Other: Mantra Chikitsa
Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
Other Name: Mantra therapy

No Intervention: Wait list control
Rest for 15 Mins



Primary Outcome Measures :
  1. Systolic Blood Pressure [ Time Frame: Change from baseline to half an hour ]
  2. Diastolic Blood Pressure [ Time Frame: Change from baseline to half an hour ]

Secondary Outcome Measures :
  1. Supine heart rate (HR) [ Time Frame: Change from baseline to half an hour ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed and stable hypertension
  • on regular medication

Exclusion Criteria:

  • Individuals diagnosed with another lung disease,
  • Have psychiatric, musculoskeletal or cardiovascular diseases,
  • Being smokers
  • Being pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03555344


Locations
Layout table for location information
India
NMP Medical Research Institute
Jaipur, Rajasthan, India, 302019
Sponsors and Collaborators
NMP Medical Research Institute
Warwick Research Services
Swamigal Trust for Vedic Science, India
Investigators
Layout table for investigator information
Study Director: Neha Sharma, PhD Warwick Research Services
Principal Investigator: Ravishankar Ramanathan Swamigal Trust for Vedic Science, India
Study Chair: Puneet Sharma NMP Medical Research Institute
Layout table for additonal information
Responsible Party: NMP Medical Research Institute
ClinicalTrials.gov Identifier: NCT03555344    
Other Study ID Numbers: NMP/10164
First Posted: June 13, 2018    Key Record Dates
Last Update Posted: July 17, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases